Expansions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Expansions
A roundup of manufacturing and service expansions.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 10

Cambridge, MA (Sept. 18)Genzyme broke ground on an expansion of its flagship manufacturing facility at Allston Landing in Boston. The $150-million project is focused on adding space for manufacturing support functions and will allow for the creation of 90 jobs.

Somerset, NJ (Sept. 17)Catalent Pharma Solutions, a provider of outsourced clinical and commercial packaging services, will expand its temperature-controlled warehouse in Bolton, United Kingdom, to meet increased customer demand for clinical-supply services, especially cold-chain storage and distribution. This expansion involves a purpose-built extension of the existing facility and is expected to be operational in June 2008. Planned features for the temperature-controlled warehouse include floor space of more than 7500 ft2, more than 2700 controlled ambient storage locations, and a 320-pallet refrigerator.

St. Louis, MO (Sept. 12)—Sigma-Aldrich will invest in a site at the Wuxi-New District Park located northwest of Shanghai, China, for its new Asia-Pacific manufacturing hub. Sigma-Aldrich expects to initially invest $25 million to acquire land rights and construct its first phase, which includes a large-scale, non-CGMP, multipurpose organic manufacturing facility dedicated to supporting its SAFC fine chemicals business unit. Construction of the new plant is set to start by the end of 2007. When fully developed, the manufacturing plant is expected to produce raw materials, key intermediates, and final products in support of SAFC's businesses. The site will also contain analytical, packaging, and warehousing facilities.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here